Complete Set of Elastic Moduli of a Spin-Crossover Solid: Spin-State Dependence and Mechanical Actuation

Molecular spin crossover complexes are promising candidates for mechanical actuation purposes. The relationships between their crystal structure and mechanical properties remain, however, not well understood. In this study, combining high pressure synchrotron Xray diffraction and nuclear inelastic scattering measurements, we assessed the effective macroscopic bulk modulus (11.5 ± 2.0 GPa), Young’s modulus (10.9 ± 1.0 GPa) and Poisson’s ratio (0.34 ± 0.04) of the spin crossover complex [FeII(HB(tz)3)2] (tz = 1,2,4-triazol-1-yl) in its low spin state. Crystal structure analysis revealed a pronounced anisotropy of the lattice compressibility, which was correlated with the difference in spacing between the molecules in different crystallographic directions. Switching the molecules from the low spin to the high spin state leads to a remarkable drop of the Young’s modulus to 7.1 ± 0.5 GPa, which was also assessed in thin film samples by means of micromechanical measurements. These results are in agreement with the high cooperativity of the spin crossover in this compound and highlight its application potential in terms of recoverable stress (21 ± 1 MPa) and work density (15 ± 6 mJ/cm3)

Etude de la faisabilité de l'allogreffe de cellules souches hématopoïétiques dans la myélofibrose primitive ou secondaire à un autre syndrome myéloprolifératif

L'objectif était d'étudier la faisabilité de l'allogreffe de cellules souches hématopoïétiques (CSH) à conditionnement myéloablatif ou d'intensité réduite dans le cas de la myélofibrose primitive ou secondaire à une polyglobulie ou à une thrombocytémie essentielles. 39 patients avec un âge médian de 49 ans (15-65) et allogreffés entre 1994 et 2008 ont été inclus dans notre étude rétrospective multicentrique. Le score de Dupriez était bas pour 9, intermédiaire pour 16 et élevé pour 14 patients, 10 étaient en phase acutisée. 15 patients ont reçu un conditionnement myéloablatif (CMA) et 24 un conditionnement d'intensité réduite (CIR). Le donneur était apparenté pour 25 patients et tous ont reçu un greffon HLA-matched (>= 9/10). La sortie d'aplasie a été effective chez tous les patients sauf un, avec une médiane de 15 jours [0-129] post greffe. Celle-ci a été plus rapide chez les patients splénectomisés ou ayant reçu un conditionnement de type CIR. 79% des patients ont développé une GVHD aigue de grade I à IV. Sur les 35 patients évaluables, 18 ont développé une GVHD chronique. La survie globale et la survie sans rechute à 3 ans étaient de 61 et 55% respectivement. La mortalité reliée au traitement (TRM) à 3 ans était de 28%. Il n'y avait aucune différence significative entre les groupes CMA et CIR en terme de survie globale ou TRM. Une thrombopénie < 100000/mm3 était associée à une survie globale inférieure (p=0.011). Notre étude confirme le potentiel curatif de l'allogreffe de CSH de type CMA ou CIR dans la myélofibrose, cependant au prix d'une TRM importante. Dans le groupe CIR, celle-ci était liée au délai trop important entre le diagnostic et la greffe qui va de paire avec un stade plus avancé de la maladie. Nous recommandons plutôt un conditionnement de type non myéloablatif pour les patients ayant un stade intermédiaire, quelque soit leur âge (jusqu'à 65 ans). Une splénectomie avant greffe ne doit pas être systématique. Les patients thrombopéniques (plaquettes < 100000/mm3) ne sont pas de bons candidats à l'allogreffe de CSH.CLERMONT FD-BCIU-Santé (631132104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial

International audienceHypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Tria

Satisfaction of Cancer Patients Treated with Oral Anticancer Medications regarding Dispensing by Community Pharmacists: A Cross-Sectional Study

Purpose. The growing choice of oral anticancer medications (OAMs) delivered in pharmacies puts the patients at the center of their own therapeutic management. Patient satisfaction regarding their pharmaceutical management is particularly important for adherence to their treatment. The aim of this study was to assess the satisfaction of patients treated with OAMs regarding their dispensing in community pharmacies. Methods. A cross-sectional study was conducted with a self-questionnaire proposed to patients in hospital centers and community pharmacies. The patient’s satisfaction regarding pharmacy dispensing was assessed with a visual analogue scale. Answers to questions about the quality of information they received from health professionals were recorded. The patient’s adherence to their medication was assessed with the 8-item Morisky Medication Adherence Scale (MMAS-8). Symptoms and quality of life were recorded with the QLQ-C30 questionnaire. Results. Ninety-one patients were included in the analysis. The median score of satisfaction was 89 (interquartile range: 68, 100), and 49.5% had a satisfaction score ≥90/100. Satisfaction scores were higher for patients reporting information from pharmacists for the method of administration, the management of adverse effects, and drug interactions than for patients reporting no information from pharmacists. Patient satisfaction was not related to MMAS-8 scores, symptoms, or quality of life. Multivariate analysis of patient satisfaction revealed a positive relationship with information on the administration method provided by pharmacists. Conclusions. The level of information provided on OAMs to patients should be the same between pharmacists and oncologists. Good medication dispensing practices by the pharmacist are important components of patient care and satisfaction. We encourage pharmacists to provide more medication information to their patients

Human herpesvirus 6 infection after autologous stem cell transplantation: A multicenter prospective study in adult patients

International audienc

Prevention of Venous Thrombotic Events in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatric-Inspired Protocol - a Graall Study

58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego, CA, DEC 03-06, 2016International audienc

Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study.

Patients undergoing treatment of acute lymphoblastic leukemia (ALL) are at risk for thrombosis, caused in part by the use of l-asparaginase (L-ASP). Antithrombin (AT) replacement has been suggested to prevent venous thromboembolism (VTE) and thus may increase exposure to ASP. We report herein the results of the prophylactic replacement strategy in the pediatrics-inspired prospective GRAALL-2005 study. Between 2006 and 2014, 784 adult patients with newly diagnosed Philadelphia- ALL were included. The incidence rate of VTE was 16%, with 69% of cases occurring during induction therapy. Most patients received AT supplementation (87%). After excluding patients who did not receive L-ASP or who developed thrombosis before L-ASP, AT supplementation did not have a significant impact on VTE. Administration of fibrinogen concentrates was associated with an increased risk of VTE, whereas transfusion of fresh frozen plasma had no effect. Heparin prophylaxis was associated with an increased risk of VTE. Prophylactic measures were not associated with an increased risk of grade 3 to 4 bleeding complications. The rate of VTE recurrence after L-ASP reintroduction was 3% (1 of 34). In ALL patients receiving L-ASP therapy, the use of fibrinogen concentrates may increase the risk of thrombosis and should be restricted to rare patients with hypofibrinogenemia-induced hemorrhage. VTE developed despite extensive AT supplementation, which suggests the need for additional prophylactic measures. Although this large descriptive study was not powered to demonstrate the efficacy of these prophylactic measures, it provides important insight to guide future trial design. This trial was registered at www.clinicaltrials.gov as #NCT00327678